Analysts have issued a financial statement on the first quarter report from BioLife Solutions, Inc. (NASDAQ:BLFS)

BioLife Solutions, Inc. (NASDAQ:BLFS) investors will be delighted with the company posting strong numbers with its latest results. Revenue and loss per share were both better than expected, with revenue of US$17 million leading estimates by 4.2%. Statutory losses were lower than analysts’ expectations at $0.03 per share. Analysts typically update their forecasts with each earnings report, and we can judge from their estimates if their view of the business has changed or if there are new concerns to consider. So we’ve collected the latest post-earnings statutory consensus estimates to see what might be in store for next year.

Check out our latest analysis for BioLife Solutions


Based on the latest results, the current consensus of BioLife Solutions’ eight analysts calls for revenue of US$110.4 million in 2021, which would reflect a major 109% increase in sales over the past 12 months. Losses are expected to drop significantly, decreasing 93% to US$0.05. Still, prior to the latest results, analysts were forecasting revenue of $105.6 million and losses of $0.039 per share in 2021. So it’s pretty clear that analysts have mixed views on BioLife Solutions even after this update. day ; although they increased their revenue, it came at the cost of a huge increase in losses per share.

The consensus price target remained unchanged at US$56.43, which seems to suggest that higher expected losses should not have a long-term impact on valuation. The consensus price target is only an average of individual analyst targets, so it might be useful to see how wide the range of the underlying estimates is. Currently, the most bullish analyst values ​​BioLife Solutions at $65.00 per share, while the most bearish one values ​​it at $50.00. Still, with such a narrow range of estimates, it suggests analysts have a pretty good idea of ​​what they think the company is worth.

Looking now at the big picture, one way to understand these forecasts is to see how they compare to past performance and industry growth estimates. It is clear from the latest estimates that BioLife Solutions’ growth rate is set to accelerate significantly, with forecast annualized revenue growth of 168% through the end of 2021 significantly faster than its historical growth of 41%. per year over the past five years. Compare that with other companies in the same industry, which are expected to grow revenue by 7.9% annually. It seems clear that while growth prospects are brighter than in the recent past, analysts also expect BioLife Solutions to grow faster than the industry as a whole.

The essential

The most important thing to note is the expectation of increased losses next year, suggesting that all may not be well at BioLife Solutions. Luckily, they also updated their revenue estimates and expect revenue to grow faster than the industry as a whole. There was no real change from the consensus price target, suggesting that the company’s intrinsic value has not undergone major changes with the latest estimates.

With that in mind, we wouldn’t be too quick to come to a conclusion on BioLife Solutions. Long-term earnings power is much more important than next year’s earnings. We have forecasts for BioLife Solutions until 2025, and you can view them for free on our platform here.

And what about the risks? Every business has them, and we’ve spotted 3 warning signs for BioLife Solutions (1 of which is a little worrying!) that you should know about.

This Simply Wall St article is general in nature. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to bring you targeted long-term analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative materials. Simply Wall St has no position in the stocks mentioned.

Feedback on this article? Concerned about content? Get in touch with us directly. You can also email the editorial team (at)

Marianne R. Winn